Induction Chemotherapy + Concurrent Chemoradiotherapy (Cisplatin-based)
Treatment for Nasopharynx Cancer
Typical Dosage: Induction chemotherapy (e.g., Gemcitabine + Cisplatin) followed by Cisplatin-based CCRT (66-70 Gy radiation with weekly Cisplatin 40 mg/m2).
Effectiveness
88%
Safety Score
20%
Clinical Trials
8
Participants
15K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
20
DangerousModerateSafe
Treatment Details
Dosage Range
Induction chemotherapy (e.g., Gemcitabine + Cisplatin) followed by Cisplatin-based CCRT (66-70 Gy radiation with weekly Cisplatin 40 mg/m2).
Time to Effect
Within weeks for induction; full effect after CCRT (months)
Treatment Duration
4-6 months (2-4 cycles induction + 6-7 weeks CCRT)
Evidence Quality
HIGHConfidence Score
88%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$15,000
Monitoring:$25,000
Side Effect Mgmt:$20,000
Total Annual:$60,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODQALYs Gained
2.5
Outcome-Based Costs
Cost per Responder
$66,667
Cost per Remission
$75,000
Comparison vs Concurrent Chemoradiotherapy (Cisplatin-based)
Cost Difference
+$20,000/year
More expensive
QALY Difference
+0.50 QALYs
Better outcomes
Dominance
No dominance
Prescription Access Economics
Risk Assessment
Requires Monitoring
YesNeeds lab work/checkups
Induction Chemotherapy + Concurrent Chemoradiotherapy (Cisplatin-based) Outcomes
for Nasopharynx Cancer
Efficacy Outcomes
Overall Effectiveness
+88%
Response Rate
+90%
Remission Rate
+80%
Common Side Effects
Myelosuppression
+60%
Nausea/Vomiting
+80%
Mucositis
+70%
Xerostomia
+90%
Fatigue
+80%
Nephrotoxicity
+25%
Ototoxicity
+15%
Sources:
Active Clinical Trials
9 active trials recruiting for Induction Chemotherapy + Concurrent Chemoradiotherapy (Cisplatin-based) in Nasopharynx Cancer
Modulation Therapy for Locally Advanced NPC Based on Plasma EBV DNA Level Post-ICT
NCT05628922RECRUITINGPHASE2
198 participants
INTERVENTIONAL
Shanghai, China
Started: Jul 2, 2022
Cisplatin-based and Carboplatin-based Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma
NCT03919552RECRUITINGPHASE3
482 participants
INTERVENTIONAL
Guangzhou, China
Started: Jan 31, 2018
Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal Carcinoma
NCT07362979RECRUITINGPHASE2
243 participants
INTERVENTIONAL
Dongguan, China +3 more
Started: Mar 12, 2026
Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy
NCT07328841RECRUITINGPHASE3
456 participants
INTERVENTIONAL
Guangzhou, China +11 more
Started: Nov 18, 2025
Reduced-dose RT With/Without CCT Versus Standard CCRT for High-risk LANPC Who Achieved CR Post Induction Chemotherapy
NCT06092957RECRUITINGPHASE3
504 participants
INTERVENTIONAL
Guangzhou, China
Started: Oct 9, 2023
Under Whole-course of Immunotherapy, Gradient Fractionated RT with CCT Versus CFRT with CCT for LANPC Who Achieved PR Post Induction Chemotherapy.
NCT06675214RECRUITINGPHASE3
586 participants
INTERVENTIONAL
Zhuhai, China
Started: Jul 30, 2024
Nituzumab (Taixinsheng ®） A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Study on the Efficacy and Safety of Combined Induction Chemotherapy for Locally Advanced Nasopharyngeal Carcinomatreatment of Locally Advanced Nasopharyngeal Carcinoma
NCT05508347RECRUITINGPHASE2
170 participants
INTERVENTIONAL
Chengdu, China
Started: Apr 20, 2022
Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
NCT06239727RECRUITINGPHASE3
593 participants
INTERVENTIONAL
Fuzhou, China +25 more
Started: Mar 1, 2024
Proton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III Trial
NCT07340515RECRUITINGPHASE3
300 participants
INTERVENTIONAL
Jinan, China
Started: Dec 15, 2025